Opthea LTD (OPTEY) — SEC Filings

Overview

Opthea LTD (OPTEY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 20, 2025: Opthea Limited filed a Form 6-K on November 20, 2025, reporting information for the month of November 2025. The filing includes a press release dated November 20, 2025, as Exhibit 99.1. Opthea Limited is a biotechnology company focused on biological products.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 6 bullish, 2 bearish, 42 neutral. The dominant filing sentiment for Opthea LTD is neutral.

Filing Type Overview

Opthea LTD (OPTEY) has filed 46 6-K, 2 20-F, 1 SC 13G/A, 1 20-F/A with the SEC between Jul 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Opthea Ltd Files 6-K Report — 6-K · Nov 20, 2025 Risk: low
  Opthea Limited filed a Form 6-K on November 20, 2025, reporting information for the month of November 2025. The filing includes a press release dated November 2
• 6-K Filing — 6-K · Nov 12, 2025
• 6-K Filing — 6-K · Oct 31, 2025
• Opthea Ltd Files 6-K, Incorporates by Reference — 6-K · Oct 30, 2025 Risk: low
  Opthea Limited filed a Form 6-K on October 30, 2025, to report information for the month of October 2025. The filing indicates that Opthea Limited is a foreign
• Opthea Appoints New Company Secretary — 6-K · Oct 27, 2025 Risk: low
  Opthea Limited, an Australian biotechnology company, announced the appointment of Ms. Sarah Jane Martin as Company Secretary, effective October 27, 2025. She wi
• Opthea Ltd Files Notice of Annual General Meeting — 6-K · Oct 10, 2025 Risk: low
  Opthea Limited filed a Form 6-K on October 10, 2025, reporting its Notice of Annual General Meeting. The filing is for the month of October 2025 and Opthea Limi
• Opthea Secures A$10.8M R&D Tax Incentive — 6-K · Oct 6, 2025 Risk: low
  Opthea Limited announced on October 6, 2025, that it received A$10.8 million from the Australian Government's Research and Development (R&D) Tax Incentive progr
• Opthea Scraps Flagship Drug, Pays $20M to Exit Funding Deal — 20-F · Sep 15, 2025 Risk: high
  Opthea Ltd (OPTEY) reported a significant strategic shift for the fiscal year ended June 30, 2025, following the failure of its sozinibercept Phase 3 trials. Th
• Opthea Ltd Files Preliminary Final Report — 6-K · Aug 29, 2025 Risk: low
  Opthea Limited filed a Form 6-K on August 29, 2025, reporting its Appendix 4E Preliminary Final Report for the fiscal year ending June 30, 2025. This filing is
• Opthea Ltd Files 6-K with Corporate Update — 6-K · Aug 20, 2025 Risk: low
  Opthea Limited filed a Form 6-K on August 20, 2025, reporting on its corporate activities for August 2025. The filing includes an investor presentation as Exhib
• Opthea Ltd. Files August Corporate Update (6-K) — 6-K · Aug 19, 2025 Risk: low
  Opthea Ltd. filed a Form 6-K on August 19, 2025, reporting a corporate update for August 2025. The filing includes Exhibit 99.1, which details the corporate upd
• Opthea Ltd Files 6-K Corporate Update — 6-K · Jun 2, 2025 Risk: medium
  Opthea Limited filed a Form 6-K on June 2, 2025, to provide a corporate update. The filing includes Exhibit 99.1, which details the company's latest development
• Opthea Ltd Files 6-K Corporate Update — 6-K · Apr 10, 2025 Risk: low
  Opthea Limited filed a Form 6-K on April 10, 2025, to provide a corporate update. The filing includes Exhibit 99.1, which details the company's latest developme
• Opthea Discontinues Wet AMD Trials — 6-K · Mar 31, 2025 Risk: high
  Opthea Limited announced on March 31, 2025, its decision to discontinue its Phase 3 clinical trials for its wet age-related macular degeneration (AMD) therapy.
• Opthea's Wet AMD Trial Meets Primary Endpoint — 6-K · Mar 24, 2025 Risk: medium
  Opthea Ltd announced topline results for its Phase 3 COAST trial of sozinibercept for wet age-related macular degeneration (AMD) on March 24, 2025. The trial me
• Opthea Publishes Phase 2b Wet AMD Trial Results — 6-K · Mar 3, 2025 Risk: medium
  Opthea Limited announced on March 3, 2025, the publication of its Phase 2b clinical trial results for its wet age-related macular degeneration (AMD) therapy. Th
• Opthea Ltd Files Half Year Results and Business Updates — 6-K · Feb 28, 2025 Risk: medium
  Opthea Limited filed a Form 6-K on February 28, 2025, reporting its half-year results and business updates. The filing includes Exhibit 99.1, detailing these re
• Opthea Completes Key Drug Product PPQ Campaign — 6-K · Feb 26, 2025 Risk: medium
  Opthea Limited announced on February 26, 2025, the successful completion of its Drug Product Process Qualification (PPQ) campaign for its lead therapeutic candi
• Opthea Completes Final Patient Visit for COAST Trial — 6-K · Feb 18, 2025 Risk: medium
  Opthea Limited announced on February 18, 2025, that it has completed the final patient visit for Week 52 in its COAST Phase 3 clinical trial. This trial is eval
• Opthea to Present at Oppenheimer Healthcare Conference — 6-K · Feb 7, 2025 Risk: low
  Opthea Limited announced on February 7, 2025, that it will present at the Oppenheimer Healthcare Conference. The company, based in South Yarra, Victoria, Austra
• Opthea Presents Wet AMD Trial Data at Macula Society Meeting — 6-K · Feb 6, 2025 Risk: medium
  Opthea Ltd. (ASX:OPT, NASDAQ:OPT) announced on February 6, 2025, that data from its Phase 3 ShOEnguARD trial for its wet age-related macular degeneration (AMD)
• Opthea Ltd Files 6-K, Includes Investor Day Press Release — 6-K · Jan 28, 2025 Risk: low
  Opthea Limited filed a Form 6-K on January 28, 2025, reporting on its activities for the month of January 2025. The filing includes a press release regarding Op
• Opthea Ltd Updates Corporate Presentation — 6-K · Jan 13, 2025 Risk: low
  On January 13, 2025, Opthea Limited posted an updated corporate presentation on its website, accessible via ir.opthea.com. The presentation includes current est
• Opthea Ltd to Host Investor Days in NY and Australia — 6-K · Jan 8, 2025 Risk: medium
  Opthea Limited announced on January 8, 2025, that it will host investor days in New York and Australia. These events will provide updates on the company's devel
• Opthea's DME Trial Data Published in NEJM — 6-K · Jan 7, 2025 Risk: medium
  Opthea Limited announced on January 7, 2025, the publication of its Phase 3 trial data for sozinibercept in the New England Journal of Medicine. The study, whic
• Opthea to Present at J.P. Morgan Healthcare Conference — 6-K · Dec 19, 2024 Risk: low
  Opthea Limited announced on December 19, 2024, that it will present at the 43rd Annual J.P. Morgan Healthcare Conference. The conference is scheduled to take pl
• Opthea's Wet AMD Program Featured at FLORetina 2024 — 6-K · Nov 26, 2024 Risk: medium
  Opthea Ltd. announced on November 26, 2024, that its wet AMD program will be presented at the FLORetina 2024 conference. The presentation will feature data from
• Opthea to Present at Citi Global Healthcare Conference — 6-K · Nov 25, 2024 Risk: low
  Opthea Limited announced on November 25, 2024, that it will participate in the Citi 2024 Global Healthcare Conference. The company will present its latest devel
• Opthea Ltd Updates Corporate Presentation — 6-K · Nov 19, 2024 Risk: low
  On November 19, 2024, Opthea Limited posted an updated corporate presentation on its website, accessible via the "Investor Relations" section at ir.opthea.com.
• Opthea Ltd Announces AGM Results & A$15.9M Tax Incentive — 6-K · Nov 15, 2024 Risk: medium
  Opthea Limited filed a Form 6-K on November 15, 2024, detailing several announcements. Key among these are the Chairman's Address at the Annual General Meeting
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Opthea's Wet AMD Program Featured at Ophthalmology Events — 6-K · Nov 12, 2024 Risk: medium
  Opthea Ltd. (ASX:OPT, NASDAQ:OPT) announced on November 12, 2024, that its wet age-related macular degeneration (AMD) program was featured at key ophthalmology
• Opthea Ltd. to Present at November Investor Conferences — 6-K · Nov 4, 2024 Risk: low
  Opthea Ltd. announced its participation in upcoming investor conferences throughout November 2024. The company will present its latest developments and engage w
• Opthea Ltd. Files Quarterly Report and Cashflow Update — 6-K · Nov 1, 2024 Risk: medium
  Opthea Ltd. filed a Form 6-K on November 1, 2024, reporting its quarterly results and cash flow for the period ending October 31, 2024. The filing includes a pr
• Opthea Ltd Files October 2024 Corporate Presentation — 6-K · Oct 28, 2024 Risk: medium
  Opthea Limited filed a Form 6-K on October 28, 2024, to report its corporate presentation from October 2024. The filing includes a press release detailing the p
• Opthea Ltd Files Notice of Annual General Meeting — 6-K · Oct 16, 2024 Risk: low
  Opthea Limited filed a Form 6-K on October 16, 2024, to report its Notice of Annual General Meeting. The filing includes a press release detailing this notice,
• Opthea Presents Wet AMD Program at Innovate Retina — 6-K · Oct 10, 2024 Risk: low
  Opthea Limited announced on October 10, 2024, that its wet AMD program will be presented at the Innovate Retina conference. This presentation will likely cover
• Opthea Appoints New CMO and CFO Ahead of Phase 3 Data — 6-K · Oct 8, 2024 Risk: medium
  Opthea Limited announced on October 8, 2024, the appointment of Dr. Moira Miller as Chief Medical Officer and Mr. Matthew Johnson as Chief Financial Officer. Th
• Opthea to Present at UBS Ophthalmology Day — 6-K · Sep 30, 2024 Risk: low
  Opthea Ltd announced its participation in the UBS Virtual Ophthalmology Day 2024, scheduled for September 2024. The company will present its latest advancements
• Opthea Ltd Files 6-K, Includes Euretina Symposium Press Release — 6-K · Sep 26, 2024 Risk: low
  Opthea Limited filed a Form 6-K on September 26, 2024, reporting on events for the month of September 2024. The filing includes a press release regarding the Eu
• Opthea Joins S&P/ASX 300 Index — 6-K · Sep 23, 2024 Risk: low
  Opthea Limited announced on September 23, 2024, that it has been included in the S&P/ASX 300 Index. This inclusion is a significant milestone for the company, r
• Opthea Ltd Files 20-F/A Amendment — 20-F/A · Sep 20, 2024 Risk: medium
  Opthea Ltd filed an amendment to its 20-F form on September 20, 2024, for the period ending June 30, 2024. The filing details its financial position and busines
• Opthea to Present Sozinibercept Data at EURETINA Congress — 6-K · Sep 18, 2024 Risk: medium
  Opthea Limited announced on September 18, 2024, that it will have a significant presence at the 24th EURETINA Congress and EURETINA Innovation Spotlight. The co
• Opthea to Present OCS-01 Data at EURETINA Congress — 6-K · Sep 10, 2024 Risk: medium
  Opthea Limited announced a significant presence at the 24th EURETINA Congress and EURETINA Innovation Spotlight, taking place in September 2024. The company wil
• Opthea Ltd Files September 2024 Corporate Presentation — 6-K · Sep 9, 2024 Risk: medium
  Opthea Limited filed a Form 6-K on September 9, 2024, to report its corporate presentation for September 2024. The filing includes a press release detailing the
• Opthea Ltd Announces Executive Leadership Changes — 6-K · Sep 5, 2024 Risk: medium
  Opthea Limited announced executive leadership changes and senior hires on September 5, 2024. The company, focused on biological products, has appointed new pers
• Opthea to Present at H.C. Wainwright & Cantor Conferences — 6-K · Sep 3, 2024 Risk: low
  Opthea Limited announced its participation in two upcoming investor conferences: the H.C. Wainwright 26th Annual Global Investment Conference and the Cantor 202
• Opthea Ltd Files 20-F for FY2024 — 20-F · Aug 30, 2024 Risk: medium
  Opthea Ltd filed its 20-F for the fiscal year ending June 30, 2024. The filing details its business operations in biological products, specifically focusing on
• Opthea to Present at H.C. Wainwright Ophthalmology Conference — 6-K · Aug 8, 2024 Risk: low
  Opthea Limited announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. The company will present its l
• Opthea Adds Retina Experts to Medical Advisory Board — 6-K · Jul 17, 2024 Risk: low
  Opthea Limited announced on July 17, 2024, the appointment of several international retina thought leaders to its Medical Advisory Board. This move aims to bols

Risk Profile

Risk Assessment: Of OPTEY's 47 recent filings, 2 were flagged as high-risk, 21 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Sarah Jane Martin
• Andrew Tyndale
• Jeremy Levin
• Kathy Connell
• Dr. Moira Miller
• Mr. Matthew Johnson
• Frederic Guerard

Industry Context

The biopharmaceutical industry, particularly in ophthalmology, is characterized by high R&D costs and significant regulatory hurdles. Companies like Opthea focus on developing novel therapies for unmet medical needs, such as wet AMD. The competitive landscape involves established players and emerging biotech firms, with success often hinging on clinical trial outcomes and intellectual property.

Top Tags

biotech (16) · investor-relations (8) · ophthalmology (8) · corporate-update (6) · drug-development (5) · conference-presentation (4) · conference-participation (4) · regulatory-filing (3) · press-release (3) · biotechnology (3)

Key Numbers

• Commission File Number: 001-39621 — Identifies Opthea Limited's SEC filing history.
• Form S-8 File Number: 333-251052 — This 6-K is incorporated into this registration statement.
• R&D Tax Incentive: A$10.8 million — Funding received from the Australian Government to support research and development.
• Cash payment to DFA Investors: $20M — Part of the settlement to terminate the Development Funding Agreement on August 19, 2025.
• Ordinary shares issued: 136,661,003 — Issued to DFA Investors as part of the DFA termination, representing 9.99% of outstanding shares.
• Dilution to shareholders: 9.99% — Resulted from the issuance of ordinary shares to DFA Investors on August 19, 2025.
• Ordinary Shares outstanding: 1,231,817,008 — Total ordinary shares outstanding as of June 30, 2025, including shares underlying ADSs.
• American Depositary Shares outstanding: 12,430,322 — Total ADSs outstanding as of June 30, 2025.
• Ordinary shares per ADS: 8 — Each American Depositary Share represents eight ordinary shares.
• Final Patient Visit: Week 52 — Indicates completion of the primary data collection phase for the COAST trial.
• Patients: 650 — Number of participants in the Phase 3 trial for sozinibercept.
• S&P/ASX 300 Index: 300 — Represents the 300 largest companies on the ASX
• Ordinary Share Member: 0.3451 — Represents a share class or metric related to ordinary shares.
• Expiry of January 2025 Member: 0.3220 — Likely related to options or rights expiring in January 2025.
• Performance Rights Member: 0.2640 — Refers to equity-based compensation in the form of performance rights.

Related Companies

OPT · ASX:OPT · NASDAQ:OPT

Frequently Asked Questions